Ask about this productRelated genes to: PDSS2 antibody
- Gene:
- PDSS2 NIH gene
- Name:
- decaprenyl diphosphate synthase subunit 2
- Previous symbol:
- C6orf210
- Synonyms:
- bA59I9.3, COQ1B
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 2003-11-26
- Date modifiied:
- 2019-03-13
Related products to: PDSS2 antibody
Related articles to: PDSS2 antibody
- : Freezing of gait (FOG) and sleep disturbances are common in people with Parkinson's disease (PwPD). A bidirectional association between them has been suggested, but quantitative evaluations are scarce. This study aimed to compare sleep disturbances in mild-to-moderate PwPD with (PD+FOG) and without FOG (PD-FOG), and to assess the association between FOG severity and sleep parameters. : Data from 54 PwPD with disease stage <4 and no severe cognitive decline were included (27 PD+FOG and 27 propensity score-matched for age, sex, and disease duration PD-FOG). Demographics and clinical variables were collected. Clinical assessment included the new freezing of gait questionnaire (NFOG-Q), Parkinson's Disease Sleep Scale (PDSS-2), Epworth Sleepiness Scale (ESS) and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Mann-Whitney U, Fisher's exact and Spearman's tests were used for group comparisons and correlations, respectively. : Significant differences were observed between PD+FOG and PD-FOG groups in MDS-UPDRS part II ( = 0.011) and part IV ( = 0.011), with higher scores in PD+FOG participants. No significant differences were found in PDSS-2 or ESS between the two groups. A significant moderate positive correlation was found between NFOG-Q score and PDSS-2 (ρ = 0.416; = 0.044) in PD+FOG participants. : FOG severity was positively associated with sleep disturbances within the PD+FOG group. However, no significant difference in sleep quality or excessive daytime sleepiness was found between PD+FOG and PD-FOG after propensity score matching. PD+FOG participants experienced more severe motor complications and greater impairment in daily activities compared to PD-FOG. - Source: PubMed
Publication date: 2026/04/30
Milane TracyBianchini EdoardoDe Carolis LanfrancoSuppa AntonioSalvetti MarcoHansen ClintMarano MassimoRinaldi DomizianaVuillerme Nicolas - Coenzyme Q10 (CoQ10) is an essential lipid-soluble antioxidant and a key component of the mitochondrial electron transport chain, playing critical roles in cellular redox homeostasis and energy metabolism. Although organ-specific differences in CoQ10 levels have been reported in humans, the mechanisms underlying tissue-specific regulation of CoQ10 remain poorly understood. Moreover, species differences in the predominant CoQ isoform limit the suitability of conventional rodent models for studying human CoQ10 metabolism, aging, and disease.In this study, we aimed to explore factors contributing to organ-specific CoQ10 levels and to establish fundamental reference data for medaka (Oryzias latipes), a vertebrate model that endogenously synthesizes CoQ10. CoQ10 concentrations in multiple organs were quantified by high-performance liquid chromatography. Levels of vitamin E and free cholesterol were also measured. Mitochondrial DNA (mtDNA) content was assessed as an index of mitochondrial abundance, and expression of CoQ10 biosynthetic enzymes, the CoQ-binding protein prosaposin (Psap), and 3-hydroxy-3-methylglutaryl-CoA reductase was analyzed by RT-qPCR.CoQ10 was detected in all organs examined, with the highest levels observed in the heart and liver, followed by the kidney and brain, and lower levels in skeletal muscle and the digestive tract. No significant sex-dependent differences were observed. CoQ10 levels were positively associated with PDSS2 expression and mtDNA content, while Psap expression showed strong positive correlations with multiple CoQ-related genes.These findings provide insight into factors associated with tissue-specific CoQ10 distribution and support medaka as a physiologically relevant model for investigating CoQ10 metabolism, oxidative stress, aging, and disease. - Source: PubMed
Publication date: 2026/05/26
Tomita ShogoOkamoto MizuhoNonaka HirotoTajima MomokaMaeda AyakaOkuizumi RenaFujisawa AkioYamamoto YorihiroKashiba Misato - Parkinson's disease (PD) causes multiple non-motor symptoms (NMSs), such as insomnia, anxiety, and fatigue, that worsen the quality of life. Pharmacological options offer limited relief, prompting interest in acupuncture as an adjunctive therapy. - Source: PubMed
Publication date: 2026/05/07
Cui YizhiXue RuidongZhang BoHuo HongZhang QianshiGao BingjieZhao YanpeiMao ShenglunZhong WeiboZhao Jiaqi - Adaptive deep brain stimulation (aDBS) dynamically modulates stimulation parameters in real time based on ongoing neural activity, potentially overcoming key limitations of conventional continuous DBS (cDBS) in Parkinson's disease (PD). - Source: PubMed
Publication date: 2026/05/08
Soares CarolinaBorges GabrielFerreira-Pinto Manuel J - Growth differentiation factor 15 (GDF-15) has emerged as a potential biomarker for neurodegenerative diseases. Although elevated serum GDF-15 levels have been reported in Parkinson's disease (PD), their association with clinical features has not been fully characterized. - Source: PubMed
Publication date: 2026/04/29
Miyaue NoriyukiYabe HayatoYasugi MinaNagai Masahiro